Evidence map›Paper›PMID 42653244›Full record

ArticleInternational journal of molecular sciences2026

1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.

Mariagrazia Ruvoletto, Santina Quarta, Elena Rampazzo, Lorena Lucatello, Roberto Luisetto, Gianmarco Villano, Veronica Di Paolo, Alessandra Biasiolo, Marco Di Pascoli, Luigi Quintieri and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mariagrazia RuvolettoDepartment of Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.ORCID 0000-0001-5507-6422
Santina QuartaDepartment of Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.ORCID 0000-0002-9348-1485
Elena RampazzoDepartment of Women's and Children's Health, University of Padova, Via Giustiniani, 3, 35128 Padova, Italy.ORCID 0000-0002-5232-757X
Lorena LucatelloDepartment of Comparative Biomedicine and Food Science, University of Padova, Viale dell'Università 16, 35020 Legnaro, Italy.
Roberto LuisettoDepartment of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Gianmarco VillanoDepartment of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Veronica Di PaoloDepartment of Comparative Biomedicine and Food Science, University of Padova, Viale dell'Università 16, 35020 Legnaro, Italy.ORCID 0000-0003-2706-6774
Alessandra BiasioloDepartment of Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.
Marco Di PascoliDepartment of Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.ORCID 0000-0001-6996-3196
Luigi QuintieriLaboratory of Drug Metabolism, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo Egidio Meneghetti 2, 35131 Padova, Italy.ORCID 0000-0001-7403-0921
Francesca CapolongoDepartment of Comparative Biomedicine and Food Science, University of Padova, Viale dell'Università 16, 35020 Legnaro, Italy.ORCID 0000-0002-2848-0582
Luca PersanoDepartment of Women's and Children's Health, University of Padova, Via Giustiniani, 3, 35128 Padova, Italy.ORCID 0000-0002-0050-3666
Patrizia PontissoDepartment of Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.ORCID 0000-0003-2077-9202

Funding

Department of Women's and Children's Health University of Padua N/ANational Institute of Health RF-2019-12369984
6 · The paper itself

Abstract

Glioblastoma multiforme is the most aggressive primary brain tumor in adults, which displays extremely poor prognosis. Protease-activated receptor 2 (PAR2) and its downstream effector SerpinB3 are overexpressed in aggressive glioblastomas. In this study we evaluated the antitumor activity of 1-piperidine propionic acid (1-PPA), an allosteric PAR2 inhibitor, in in vitro preclinical models of glioblastoma. PAR2 and SerpinB3 were analyzed at the transcriptional and protein level in glioblastoma cell lines and primary cultures. These were treated with 1-PPA alone or in association with temozolomide (TMZ) and the effects evaluated by Incucyte

Indexed as

Brain NeoplasmsGlioblastomaPiperidinesPropionatesReceptor, PAR-2SerpinsSignal TransductionAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationHumansMiceTemozolomidePiperidinesPropionatespropionic acidReceptor, PAR-2SerpinsTemozolomide1-piperidine propionic acidblood–brain barrierglioblastomaprotease-activated receptor-2SerpinB3

Identifiers

PMID42653244
PMCPMC13513849

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.